BOT - Anything but charting, page-9275

Does anyone else think we are going to looking at crazy amounts of $$, when we look at targeting just 1% of sufferers to make a 10x increase in shareprice.

BOT have the only next generation medication for the condition, therefore not best in class, Sofdra is the ONLY medication in its class!!

I believe management will be secretly planning for when BOT have >20% of people with this condition wanting BOT's product, why would people not want the best medication (really the only prescription medication), i know i would.

BOT can only really skyrocket from here, it will be a happy couple of years for long termers.